CRS signs on with Bayer for early trials

CRS CEO Torben Thomsen

German contract researcher CRS has inked a deal with Bayer, signing up to conduct Phase I and II trials for cardiovascular and women's health treatments.

The long-term deal builds upon an existing relationship between the two, CRS said, and under the new partnership CRS will take over some of Bayer's clinical pharmacology units, integrating them into its German research centers. In the process, the CRO will have expanded its clinical capabilities in cardiology and gynecology.

"We're very proud to have built up a relationship with Bayer HealthCare based on trust and proven performance, which will now be elevated to a strategic partnership," CEO Torben Thomsen said in a statement. "We welcome the new, highly qualified employees from Bayer HealthCare at the new sites who will help us expand our expertise in cardiovascular and gynecological indications and where we already plan to create new jobs."

For Bayer, cardiovascular and women's health drugs are among its largest targets for growth; the company has forged ahead with new studies to expand indications for Xarelto and a $1.1 billion buyout of Conceptus and its birth-control device.

Andernach-headquartered CRS employs about 280 at 8 labs across Germany, focusing largely on early-phase work but recently expanding into late-stage development, bioanalytics, data management and clinical trial supply.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.